Condition
Oncology
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 45 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
45 shownCuratively Intended Thoracic ReirradiationNCT06950073 · 2025-10-10
RECRUITINGBreast Cancer and Chemobrain : Effects of Photobiomodulation on the Improvement of Perceived Cognitive ImpairmentNCT06995443 · 2025-06-13
RECRUITINGEfficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung CancerNCT05344209 · 2022-08-12
RECRUITINGThe MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyNCT04075305 · 2019-02-01
RECRUITINGEffects of a Group Versus Individual Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Breast Cancer Patients Undergoing Active TreatmentNCT07165912 · 2026-05-01
NOT_YET_RECRUITINGEffects of a Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Breast Cancer Patients Undergoing Active TreatmentNCT06686823 · 2024-12-01
COMPLETEDA Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate CancerNCT05712174 · 2023-09-14
TERMINATEDSurvival Monitoring in Russian Cancer RegistriesNCT06043947 · 2023-08-01
ACTIVE_NOT_RECRUITINGEffectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast CancerNCT07416409 · 2023-06-10
COMPLETEDUnderstanding CARdiac Events in Breast CancerNCT05921279 · 2023-01-14
UNKNOWNSafety and Toxicity Study of IMM27M in Patients With Advanced Solid TumorNCT05235438 · 2022-06-15
UNKNOWNAnalysis of Health Status of Сomorbid Adult Patients With COVID-19 Hospitalised in Fourth Wave of SARS-CoV-2 InfectionNCT05226416 · 2022-02-21
COMPLETEDGlycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)NCT05259696 · 2022-02-11
COMPLETEDReal-time Diagnosis and Visualization of Tumor Margins in Excised Breast Specimens Using Zenith FLIM DiagnosticsNCT04683120 · 2021-12-15
SUSPENDEDIdylla EGFR Lung TrialNCT04962191 · 2021-08-01
UNKNOWNFDG (Fluorodeoxyglucose) Findings After COVID-19 VaccinationNCT05270967 · 2021-07-29
COMPLETEDProject Insight: Feasibility of a Breast Cancer Screening Decision Support ToolNCT04741503 · 2021-04-19
COMPLETEDContinuous Wireless Monitoring of Vital Signs and Automated Alerts in Participants at Home and During HospitalizationNCT05378139 · 2021-02-01
UNKNOWNProspective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With DurvalumabNCT05027165 · 2020-11-07
UNKNOWN18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed TomographyNCT04615156 · 2020-11-01
NOT_YET_RECRUITINGGiving Information Systematically and Transparently in Lung and GI Cancer Phase 2NCT04179305 · 2020-10-25
COMPLETEDAn Integrated Digital PROM-platform for Cancer Patients During the COVID-19 PandemicNCT04816656 · 2020-08-03
COMPLETEDProspective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 PandemicNCT04437719 · 2020-06-29
COMPLETEDCOVID-19 Detection Test in OncologyNCT04367870 · 2020-05-23
COMPLETEDGiving Information Systematically and Transparently in Lung and GI Cancer Phase 1NCT04158908 · 2020-01-17
COMPLETEDPantoprazole Prophylaxis Against Delayed CINV for Patients Receiving Breast Cancer ChemotherapyNCT03948477 · 2019-06-10
COMPLETEDIvabradine to Prevent Anthracycline-induced CardiotoxicityNCT03650205 · 2019-01-22
UNKNOWNLive Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid TumorsNCT03637803 · 2019-01-10
TERMINATEDSecond-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine CarcinomaNCT03837977 · 2018-11-13
COMPLETEDMagnetic Seed Localisation for Nonpalpable Breast LesionsNCT03988777 · 2018-09-10
COMPLETEDExactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)NCT05615246 · 2018-09-05
TERMINATEDInfluence of Multidisciplinary Breast Tumor Board on Physician DecisionNCT03596463 · 2018-08-13
UNKNOWNModeling of the Response to Hypofractionated Stereotactic Pulmonary IrradiationNCT03175861 · 2017-06-14
UNKNOWNEffects of an e-Home Based Symptom Management and Mindfulness Training Programme on QoL in Breast Cancer SurvivorsNCT02931864 · 2016-12-06
COMPLETEDEpidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in AlgeriaNCT02733601 · 2016-05-29
COMPLETEDComprehensive Segmental Revision SystemNCT03270982 · 2016-04-01
ACTIVE_NOT_RECRUITINGSym015 (Anti-MET) in Patients With Advanced Solid Tumor MalignanciesNCT02648724 · 2016-03-01
COMPLETEDNutritional Safety and Metabolic Benefits of Oncometabolic Surgery for Obese Gastric Cancer PatientsNCT03067012 · 2015-09-01
COMPLETEDA Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy With Surgery in paTients With Peripheral Stage I nOn-small Cell Lung Cancer cOnsidered Higher Risk of Complications From Surgical ResectionNCT02629458 · 2015-07-01
COMPLETEDSafety Study of AMG 228 to Treat Solid TumorsNCT02437916 · 2015-04-21
TERMINATEDA Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid TumorsNCT01853306 · 2013-03-18
COMPLETEDSarcopenia and Visceral Obesity in Esophageal and Gastric CancerNCT03061370 · 2010-01-01
COMPLETEDSafety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast CancerNCT00807859 · 2009-03-09
COMPLETEDDose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)NCT00413283 · 2006-12-01
COMPLETEDSafety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung CancerNCT00352950 · 2006-03-01
WITHDRAWNCommon interventions
PlaceboDRUG3Health Education ProgramBEHAVIORAL2Oncolo-GISTBEHAVIORAL2[18]F-PSMA-1007DRUG118F-2-fluoro-2-deoxy-D-glucoseDRUG1AMG 228DRUG1AMG 386 10 mg/kg, Capecitabine and LapatinibDRUG1AMG 386 10 mgkg, Paclitaxel and TrastuzumabDRUG1AMG 386 30 mg/kg, Capecitabine and LapatinibDRUG1AMG 386 30 mg/kg, Paclitaxel and TrastuzumabDRUG1AMG 954/PanitumumabDRUG1Anti-PD-1/PD-L1 treatmentDRUG1Breast Cancer Screening Decision Support ToolOTHER1Breast cancer treatmentOTHER1CarboplatinDRUG1CemiplimabBIOLOGICAL1CisplatinDRUG1Cognitive Training ProgramBEHAVIORAL1Combination Anti-HER2 Therapy (Trastuzumab + Pertuzumab or Lapatinib)DRUG1Comprehensive SRS ReplacementDEVICE1DocetaxelDRUG1E-602BIOLOGICAL1ePROMs assessmentOTHER1Esophagectomy or GastrectomyPROCEDURE1F-18 FDG PET/CT imagingDIAGNOSTIC_TEST1
Leading sponsors
Amgen
4
University of Salamanca
2
Weill Medical College of Cornell University
2
4D pharma plc
1
AbbVie
1
AHS Cancer Control Alberta
1
Anthony Magliocco
1
AstraZeneca
1
Centre Hospitalier de Valenciennes
1
Deraya University
1
Eastern Health, Canada
1
Eurasian Association of Therapists
1
Exactech
1
Fondation Hôpital Saint-Joseph
1
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1
Trial status mix
COMPLETED23
UNKNOWN8
RECRUITING4
TERMINATED4
ACTIVE_NOT_RECRUITING2
NOT_YET_RECRUITING2
SUSPENDED1
WITHDRAWN1
Phase mix
NA12
PHASE18
PHASE28
PHASE31
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.